Factors influencing medical practitioner participation in population carrier screening for cystic fibrosis

Cystic fibrosis (CF) carrier screening should be offered to people planning a pregnancy or in early pregnancy, according to current recommendations. However, research indicates rates of offering CF carrier screening are low. Health professionals (HPs) play an important role in offering population carrier screening.

[1]  M. Caramins,et al.  Socioeconomic status and uptake of reproductive carrier screening in Australia , 2020, The Australian & New Zealand journal of obstetrics & gynaecology.

[2]  W. Grody,et al.  International perspectives on the implementation of reproductive carrier screening , 2019, Prenatal diagnosis.

[3]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[4]  J. Emery,et al.  Preconception and antenatal carrier screening for genetic conditions: The critical role of general practitioners. , 2019, Australian journal of general practice.

[5]  K. Goddard,et al.  The evolving landscape of expanded carrier screening: challenges and opportunities , 2018, Genetics in Medicine.

[6]  S. Lindheim,et al.  Expanded carrier screening: a current survey of physician utilization and attitudes , 2018, Journal of Assisted Reproduction and Genetics.

[7]  M. Pertile,et al.  Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy in Australia: outcomes of 12,000 tests , 2017, Genetics in Medicine.

[8]  A. Paepe,et al.  Attitudes of cystic fibrosis patients and parents toward carrier screening and related reproductive issues , 2015, European Journal of Human Genetics.

[9]  M. Delatycki,et al.  Attitudes and opinions of pregnant women who are not offered cystic fibrosis carrier screening , 2013, European Journal of Human Genetics.

[10]  D. Amor,et al.  Population‐based genetic carrier screening for cystic fibrosis in Victoria , 2014, The Medical journal of Australia.

[11]  L. Ioannou,et al.  ‘No thanks’—reasons why pregnant women declined an offer of cystic fibrosis carrier screening , 2013, Journal of Community Genetics.

[12]  M. Delatycki,et al.  Current Practice and Attitudes of Australian Obstetricians Toward Population-Based Carrier Screening for Inherited Conditions , 2013, Twin Research and Human Genetics.

[13]  I. Schrijver,et al.  Cystic fibrosis carrier screening in obstetric clinical practice: knowledge, practices, and barriers, a decade after publication of screening guidelines. , 2011, Genetic testing and molecular biomarkers.

[14]  C. Molster,et al.  Perceptions of population cystic fibrosis prenatal and preconception carrier screening among individuals with cystic fibrosis and their family members. , 2011, Genetic testing and molecular biomarkers.

[15]  M. Aitken,et al.  A case for cystic fibrosis carrier testing in the general population , 2011, The Medical journal of Australia.

[16]  A. Archibald,et al.  Perceived relevance of genetic carrier screening: observations of the role of health-related life experiences and stage of life in decision making , 2011, Journal of Community Genetics.

[17]  M. Aitken,et al.  Evaluation of a multi‐disease carrier screening programme in Ashkenazi Jewish high schools , 2010, Clinical genetics.

[18]  Milan Macek,et al.  Benchmarks for cystic fibrosis carrier screening: a European consensus document. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[19]  M. Delatycki,et al.  Population-Based Genetic Screening for Cystic Fibrosis: Attitudes and Outcomes , 2010, Public Health Genomics.

[20]  M. Delatycki,et al.  Population‐based carrier screening for cystic fibrosis in Victoria: The first three years experience , 2009, The Australian & New Zealand journal of obstetrics & gynaecology.

[21]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[22]  Sonya Morgan,et al.  Genetic testing in New Zealand: the role of the general practitioner. , 2004, The New Zealand medical journal.

[23]  D. Driscoll,et al.  Practice patterns of obstetrician-gynecologists regarding preconception and prenatal screening for cystic fibrosis , 2004, Genetics in Medicine.

[24]  G. van der Wal,et al.  Attitudes of Potential Providers Towards Preconceptional Cystic Fibrosis Carrier Screening , 2004, Journal of Genetic Counseling.

[25]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[26]  J. Austoker,et al.  The 'new genetics' and primary care: GPs' views on their role and their educational needs. , 1999, Family practice.

[27]  S. Loader,et al.  Cystic fibrosis carrier population screening in the primary care setting. , 1996, American journal of human genetics.

[28]  R. Williamson,et al.  The views of general practitioners on community carrier screening for cystic fibrosis. , 1996, The British journal of general practice : the journal of the Royal College of General Practitioners.

[29]  S. Loader,et al.  Cystic fibrosis carrier screening: knowledge and attitudes of prenatal care providers. , 1993, American journal of preventive medicine.

[30]  R. Williamson,et al.  Attitudes to carrier screening for cystic fibrosis: a survey of health care professionals, relatives of sufferers and other members of the public. , 1991, The British journal of general practice : the journal of the Royal College of General Practitioners.

[31]  F M Farrar,et al.  ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS , 1973, Canadian family physician Medecin de famille canadien.